New Zealand markets open in 4 hours 10 minutes

MoonLake Immunotherapeutics (MLTX)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
42.04-1.62 (-3.70%)
As of 01:50PM EDT. Market open.
Currency in USD

Valuation measures4

Market cap (intra-day) 2.75B
Enterprise value 2.24B
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)N/A
Price/book (mrq)5.54
Enterprise value/revenue N/A
Enterprise value/EBITDA -41.37

Trading information

Stock price history

Beta (5Y monthly) 1.19
52-week change 354.60%
S&P500 52-week change 325.38%
52-week high 364.98
52-week low 324.31
50-day moving average 346.40
200-day moving average 352.42

Share statistics

Avg vol (3-month) 3470.49k
Avg vol (10-day) 3279.05k
Shares outstanding 562.87M
Implied shares outstanding 662.87M
Float 823.47M
% held by insiders 19.42%
% held by institutions 196.79%
Shares short (15 Apr 2024) 47.26M
Short ratio (15 Apr 2024) 414.9
Short % of float (15 Apr 2024) 428.12%
Short % of shares outstanding (15 Apr 2024) 411.54%
Shares short (prior month 15 Mar 2024) 47M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Dec 2023

Profitability

Profit margin 0.00%
Operating margin (ttm)0.00%

Management effectiveness

Return on assets (ttm)-11.21%
Return on equity (ttm)-15.14%

Income statement

Revenue (ttm)N/A
Revenue per share (ttm)N/A
Quarterly revenue growth (yoy)N/A
Gross profit (ttm)N/A
EBITDA -54.11M
Net income avi to common (ttm)-36.01M
Diluted EPS (ttm)-0.73
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)511.01M
Total cash per share (mrq)8.13
Total debt (mrq)3.7M
Total debt/equity (mrq)0.72%
Current ratio (mrq)51.59
Book value per share (mrq)8.20

Cash flow statement

Operating cash flow (ttm)-42.78M
Levered free cash flow (ttm)-24.5M